![Anne Phillips](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Anne Phillips
Director/Board Member at TREVENA, INC.
Net worth: 5 730 $ as of 30/05/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Carrie Bourdow | F | 61 | 9 years | |
Thomas Evans | M | 69 |
Vaccitech (UK) Ltd.
![]() Vaccitech (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Vaccitech (UK) Ltd. researches in and develops seasonal flu vaccines. It engages in clinical programs for universal influenza and prostate cancer, MERS, and preclinical programs for other therapeutic infectious diseases indications. The company was founded by Adrian Hill and Sarah Gilbert and is headquartered in Oxford, the United Kingdom. | 5 years |
Karen Dawes | F | 72 |
Vaccitech (UK) Ltd.
![]() Vaccitech (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Vaccitech (UK) Ltd. researches in and develops seasonal flu vaccines. It engages in clinical programs for universal influenza and prostate cancer, MERS, and preclinical programs for other therapeutic infectious diseases indications. The company was founded by Adrian Hill and Sarah Gilbert and is headquartered in Oxford, the United Kingdom. | 3 years |
Paul Sekhri | M | 66 | 2 years | |
Heather Turner | F | 51 |
Carmot Therapeutics, Inc.
![]() Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 2 years |
Gemma Brown | M | 34 | 3 years | |
Joseph Scheeren | M | 68 |
Vaccitech (UK) Ltd.
![]() Vaccitech (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Vaccitech (UK) Ltd. researches in and develops seasonal flu vaccines. It engages in clinical programs for universal influenza and prostate cancer, MERS, and preclinical programs for other therapeutic infectious diseases indications. The company was founded by Adrian Hill and Sarah Gilbert and is headquartered in Oxford, the United Kingdom. | 3 years |
Lars Green | M | 57 |
Novo Nordisk, Inc.
![]() Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | 10 years |
Stig Hansen | M | 59 |
Carmot Therapeutics, Inc.
![]() Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 16 years |
William Enright | M | 61 |
Vaccitech (UK) Ltd.
![]() Vaccitech (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Vaccitech (UK) Ltd. researches in and develops seasonal flu vaccines. It engages in clinical programs for universal influenza and prostate cancer, MERS, and preclinical programs for other therapeutic infectious diseases indications. The company was founded by Adrian Hill and Sarah Gilbert and is headquartered in Oxford, the United Kingdom. | 5 years |
Pierre Armand Morgon | M | 61 |
Vaccitech (UK) Ltd.
![]() Vaccitech (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Vaccitech (UK) Ltd. researches in and develops seasonal flu vaccines. It engages in clinical programs for universal influenza and prostate cancer, MERS, and preclinical programs for other therapeutic infectious diseases indications. The company was founded by Adrian Hill and Sarah Gilbert and is headquartered in Oxford, the United Kingdom. | 7 years |
Timothy Kutzkey | M | 49 |
Carmot Therapeutics, Inc.
![]() Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 14 years |
Adrian Hill | M | - |
Vaccitech (UK) Ltd.
![]() Vaccitech (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Vaccitech (UK) Ltd. researches in and develops seasonal flu vaccines. It engages in clinical programs for universal influenza and prostate cancer, MERS, and preclinical programs for other therapeutic infectious diseases indications. The company was founded by Adrian Hill and Sarah Gilbert and is headquartered in Oxford, the United Kingdom. | 8 years |
Sarah Gilbert | F | - |
Vaccitech (UK) Ltd.
![]() Vaccitech (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Vaccitech (UK) Ltd. researches in and develops seasonal flu vaccines. It engages in clinical programs for universal influenza and prostate cancer, MERS, and preclinical programs for other therapeutic infectious diseases indications. The company was founded by Adrian Hill and Sarah Gilbert and is headquartered in Oxford, the United Kingdom. | 8 years |
Joel S. Solomon | M | - | 9 years | |
Robin Wright | M | 59 |
Vaccitech (UK) Ltd.
![]() Vaccitech (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Vaccitech (UK) Ltd. researches in and develops seasonal flu vaccines. It engages in clinical programs for universal influenza and prostate cancer, MERS, and preclinical programs for other therapeutic infectious diseases indications. The company was founded by Adrian Hill and Sarah Gilbert and is headquartered in Oxford, the United Kingdom. | 6 years |
Richard Nelson | M | 54 | 4 years | |
Chris Ellis | M | 64 |
Vaccitech (UK) Ltd.
![]() Vaccitech (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Vaccitech (UK) Ltd. researches in and develops seasonal flu vaccines. It engages in clinical programs for universal influenza and prostate cancer, MERS, and preclinical programs for other therapeutic infectious diseases indications. The company was founded by Adrian Hill and Sarah Gilbert and is headquartered in Oxford, the United Kingdom. | 8 years |
Robert Yoder | M | 59 | 6 years | |
Alex Hammacher | M | 43 |
Vaccitech (UK) Ltd.
![]() Vaccitech (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Vaccitech (UK) Ltd. researches in and develops seasonal flu vaccines. It engages in clinical programs for universal influenza and prostate cancer, MERS, and preclinical programs for other therapeutic infectious diseases indications. The company was founded by Adrian Hill and Sarah Gilbert and is headquartered in Oxford, the United Kingdom. | 5 years |
Ozgur Kilic | M | - | - | |
Marvin Johnson | M | 61 | 3 years | |
Todd L. Wandstrat | M | - | 3 years | |
Michael Porter | M | - | - | |
Barbara Yanni | F | 69 | 10 years | |
Kelly Boothe | M | - |
Carmot Therapeutics, Inc.
![]() Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | - |
Angela Bagley | F | - | 3 years | |
Aetna Wun Trombley | M | 45 |
Carmot Therapeutics, Inc.
![]() Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 8 years |
Fahed Al Marzooqi | M | 45 | 2 years | |
Jonothan Blackbourn | M | - | 2 years | |
Minako Pazdera | M | - |
Carmot Therapeutics, Inc.
![]() Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 1 years |
Barry Shin | M | 52 | 5 years | |
John Maraganore | M | 60 |
Biotechnology Innovation Organization
![]() Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | 7 years |
Timothy Garnett | M | 63 |
Carmot Therapeutics, Inc.
![]() Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 2 years |
Timothy Garnett | - | - |
Carmot Therapeutics, Inc.
![]() Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 2 years |
Jake Nunn | M | 53 | 11 years | |
Scott Braunstein | M | 60 | 6 years | |
Peter Svennilson | M | 62 |
Carmot Therapeutics, Inc.
![]() Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 4 years |
Michael Gray | M | 53 |
Carmot Therapeutics, Inc.
![]() Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 1 years |
Joel Raskin | M | - |
Royal College of Physicians & Surgeons of Canada
![]() Royal College of Physicians & Surgeons of Canada Other Consumer ServicesConsumer Services The Royal College of Physicians & Surgeons of Canada operates a college for medical professionals. The non-profit company is based in Ottawa, Canada. The CEO of the Canadian company is Andrew Padmos. | - |
Mark Demitrack | M | 66 | 6 years | |
Raymond Cheong | M | 42 | - | |
Graham Griffiths | M | 45 | 7 years | |
Kieran Murphy | M | - |
Royal College of Physicians & Surgeons of Canada
![]() Royal College of Physicians & Surgeons of Canada Other Consumer ServicesConsumer Services The Royal College of Physicians & Surgeons of Canada operates a college for medical professionals. The non-profit company is based in Ottawa, Canada. The CEO of the Canadian company is Andrew Padmos. | - |
Mark Corrigan | M | 66 | 1 years | |
Ian Bowmer | M | - |
Royal College of Physicians & Surgeons of Canada
![]() Royal College of Physicians & Surgeons of Canada Other Consumer ServicesConsumer Services The Royal College of Physicians & Surgeons of Canada operates a college for medical professionals. The non-profit company is based in Ottawa, Canada. The CEO of the Canadian company is Andrew Padmos. | - |
Patricia Drake | F | - | 3 years | |
Yves Fradet | M | 73 |
Royal College of Physicians & Surgeons of Canada
![]() Royal College of Physicians & Surgeons of Canada Other Consumer ServicesConsumer Services The Royal College of Physicians & Surgeons of Canada operates a college for medical professionals. The non-profit company is based in Ottawa, Canada. The CEO of the Canadian company is Andrew Padmos. | 43 years |
Steven N. Chatfield | M | 67 |
Vaccitech (UK) Ltd.
![]() Vaccitech (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Vaccitech (UK) Ltd. researches in and develops seasonal flu vaccines. It engages in clinical programs for universal influenza and prostate cancer, MERS, and preclinical programs for other therapeutic infectious diseases indications. The company was founded by Adrian Hill and Sarah Gilbert and is headquartered in Oxford, the United Kingdom. | - |
Barry Brown | M | 63 | 2 years | |
Vanessa McDade | F | - | - | |
Jennifer Freeman | F | - | - | |
Steven Tuch | M | 56 | 2 years | |
Nadège Pelletier | M | 46 | 1 years | |
J. Zev Shainhouse | M | - |
Royal College of Physicians & Surgeons of Canada
![]() Royal College of Physicians & Surgeons of Canada Other Consumer ServicesConsumer Services The Royal College of Physicians & Surgeons of Canada operates a college for medical professionals. The non-profit company is based in Ottawa, Canada. The CEO of the Canadian company is Andrew Padmos. | - |
Claude R. Benedict | M | - |
Royal College of Physicians & Surgeons of Canada
![]() Royal College of Physicians & Surgeons of Canada Other Consumer ServicesConsumer Services The Royal College of Physicians & Surgeons of Canada operates a college for medical professionals. The non-profit company is based in Ottawa, Canada. The CEO of the Canadian company is Andrew Padmos. | - |
Manu Chakravarthy | M | 50 |
Carmot Therapeutics, Inc.
![]() Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 3 years |
Thomas Strack | M | - | 1 years | |
M. Ian Bowmer | M | - |
Royal College of Physicians & Surgeons of Canada
![]() Royal College of Physicians & Surgeons of Canada Other Consumer ServicesConsumer Services The Royal College of Physicians & Surgeons of Canada operates a college for medical professionals. The non-profit company is based in Ottawa, Canada. The CEO of the Canadian company is Andrew Padmos. | 5 years |
Carmen Valcarce | M | - | 17 years | |
Elizabeth M. Keiley | F | 58 | 1 years | |
David H. Schubert | M | - |
Carmot Therapeutics, Inc.
![]() Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | - |
Srini Akkaraju Akkaraju | M | 56 | - | |
Marion B. Lyver | M | - |
Royal College of Physicians & Surgeons of Canada
![]() Royal College of Physicians & Surgeons of Canada Other Consumer ServicesConsumer Services The Royal College of Physicians & Surgeons of Canada operates a college for medical professionals. The non-profit company is based in Ottawa, Canada. The CEO of the Canadian company is Andrew Padmos. | - |
George Tsoukas | M | - |
Royal College of Physicians & Surgeons of Canada
![]() Royal College of Physicians & Surgeons of Canada Other Consumer ServicesConsumer Services The Royal College of Physicians & Surgeons of Canada operates a college for medical professionals. The non-profit company is based in Ottawa, Canada. The CEO of the Canadian company is Andrew Padmos. | - |
Francesco Tallarico | M | 41 | - | |
Ralph Kern | M | 67 |
Royal College of Physicians & Surgeons of Canada
![]() Royal College of Physicians & Surgeons of Canada Other Consumer ServicesConsumer Services The Royal College of Physicians & Surgeons of Canada operates a college for medical professionals. The non-profit company is based in Ottawa, Canada. The CEO of the Canadian company is Andrew Padmos. | - |
Scott Smith | M | 61 |
Biotechnology Innovation Organization
![]() Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | 7 years |
Jay T. Evans | M | - |
Biotechnology Innovation Organization
![]() Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | 7 years |
Tim Layton | M | - |
Biotechnology Innovation Organization
![]() Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | 7 years |
Manu Vatish | M | - |
Royal College of Physicians & Surgeons of Canada
![]() Royal College of Physicians & Surgeons of Canada Other Consumer ServicesConsumer Services The Royal College of Physicians & Surgeons of Canada operates a college for medical professionals. The non-profit company is based in Ottawa, Canada. The CEO of the Canadian company is Andrew Padmos. | - |
Andrew Padmos | M | - |
Royal College of Physicians & Surgeons of Canada
![]() Royal College of Physicians & Surgeons of Canada Other Consumer ServicesConsumer Services The Royal College of Physicians & Surgeons of Canada operates a college for medical professionals. The non-profit company is based in Ottawa, Canada. The CEO of the Canadian company is Andrew Padmos. | - |
Jasenka Matisic | M | - |
Royal College of Physicians & Surgeons of Canada
![]() Royal College of Physicians & Surgeons of Canada Other Consumer ServicesConsumer Services The Royal College of Physicians & Surgeons of Canada operates a college for medical professionals. The non-profit company is based in Ottawa, Canada. The CEO of the Canadian company is Andrew Padmos. | - |
Andrew James McLean | M | 39 |
Vaccitech (UK) Ltd.
![]() Vaccitech (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Vaccitech (UK) Ltd. researches in and develops seasonal flu vaccines. It engages in clinical programs for universal influenza and prostate cancer, MERS, and preclinical programs for other therapeutic infectious diseases indications. The company was founded by Adrian Hill and Sarah Gilbert and is headquartered in Oxford, the United Kingdom. | - |
Upendranath N. Nimmagadda | M | 81 |
Royal College of Physicians & Surgeons of Canada
![]() Royal College of Physicians & Surgeons of Canada Other Consumer ServicesConsumer Services The Royal College of Physicians & Surgeons of Canada operates a college for medical professionals. The non-profit company is based in Ottawa, Canada. The CEO of the Canadian company is Andrew Padmos. | - |
Andrew Neil Smith | M | - |
Royal College of Physicians & Surgeons of Canada
![]() Royal College of Physicians & Surgeons of Canada Other Consumer ServicesConsumer Services The Royal College of Physicians & Surgeons of Canada operates a college for medical professionals. The non-profit company is based in Ottawa, Canada. The CEO of the Canadian company is Andrew Padmos. | - |
Joel Finlayson | M | - |
Royal College of Physicians & Surgeons of Canada
![]() Royal College of Physicians & Surgeons of Canada Other Consumer ServicesConsumer Services The Royal College of Physicians & Surgeons of Canada operates a college for medical professionals. The non-profit company is based in Ottawa, Canada. The CEO of the Canadian company is Andrew Padmos. | - |
Patrick Soon-Shiong | M | 71 |
Royal College of Physicians & Surgeons of Canada
![]() Royal College of Physicians & Surgeons of Canada Other Consumer ServicesConsumer Services The Royal College of Physicians & Surgeons of Canada operates a college for medical professionals. The non-profit company is based in Ottawa, Canada. The CEO of the Canadian company is Andrew Padmos. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Maxine Gowen | M | 66 |
Biotechnology Innovation Organization
![]() Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | 14 years |
Edward Myles | M | 52 | 4 years | |
Roberto Cuca | M | 57 | 5 years | |
Scott Applebaum | M | 57 | 1 years | |
Scott Myers | M | 57 | - | |
Lonnie Moulder | M | 66 | 12 years | |
William Heiden | M | 64 | 8 years | |
John M. Limongelli | M | 54 | 5 years | |
Gino Santini | M | 67 | 8 years | |
Jonathan Violin | M | 48 | 11 years | |
Jeffrey A. Frazier | M | 60 |
Novo Nordisk, Inc.
![]() Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | 10 years |
Joseph Vittiglio | M | 52 | 5 years | |
Karsten Munk Knudsen | M | 53 |
Novo Nordisk, Inc.
![]() Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | 4 years |
Robert Perez | M | 59 | 11 years | |
Linda S. Lennox | F | 59 | 5 years | |
Adam Koppel | M | 54 | 4 years | |
John Fallon | M | 76 | 6 years | |
Barbara H. Deptula | F | 69 | 7 years | |
Davey Scoon | M | 78 | 14 years | |
James Sulat | M | 73 | 6 years | |
Lesley Russell | M | 63 | 10 years | |
Georgy Egorov | M | 48 | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 66 | 66.00% |
United Kingdom | 17 | 17.00% |
Canada | 17 | 17.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Anne Phillips
- Personal Network